CMAJ • May 23, 2006; 174 (11). First published May 2, 2006; doi:10.1503/cmaj.060509
© 2006 CMA Media Inc. or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
cmaj.060509v1
174/11/1555    most recent
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wooltorton, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wooltorton, E.
Related Collections
Right arrow Maternal-fetal medicine

Health and Drug Alerts

Persistent pulmonary hypertension of the newborn and maternal use of SSRIs

Eric Wooltorton

CMAJ

Reason for posting: Major depressive disorders affect one in 10 women of reproductive age, and selective serotonin reuptake inhibitors (SSRIs), with their generally favourable efficacy and safety profiles, are the most common medications used to treat these conditions. However, the results of a recent case– control study suggest that women taking the drugs in the latter half of their pregnancy may have an increased risk of their offspring developing persistent pulmonary hypertension of the newborn (PPHN).1


Figure 19
View larger version (34K):
[in this window]
[in a new window]
  		Box 1.

 
The drugs: PPHN is a rare but serious and sometimes fatal (about 10%–20% of the time) respiratory condition (Box 1, Box 2). In the current study, 377 women who delivered children with PPHN were enrolled. They were matched to 836 control women and their infants who did not have PPHN. Six months after delivery the women were asked to identify medications used in pregnancy, health history and demographic variables including age, ethnicity, number of years of education, presence of diabetes, cigarette use, prepregnancy body mass index (BMI) and their infant's sex. The results showed use of the antidepressants in general (and SSRIs specifically) before 20 weeks' gestation was not associated with PPHN. However, after adjusting for maternal ethnicity, BMI and diabetes, women using SSRIs after 20 weeks' gestation were more likely to have a child with PPHN than matched controls (adjusted odds ratio [OR] 6.1, 95% confidence interval [CI] 2.2–16.8). Adjustment for factors such as smoking, alcohol intake and use of NSAIDs did not change the results. Of note, only about one in 20 children with PPHN had mothers who used antidepressants during their pregnancy (a proportion similar to the control group). SSRIs used included citalopram, fluoxetine, paroxetine and sertraline.


Figure 29
View larger version (33K):
[in this window]
[in a new window]
  		Box 2.

 

The potential mechanism of this adverse effect is not certain, but SSRIs, which pool in the fetal lungs, may inihibit nitric oxide synthesis.1 Alternatively, increased serotonin levels may vasoconstrict pulmonary vessels, or cause pulmonary smooth muscle cell proliferation and increased pulmonary vascular resistance.1

What to do: These findings add to previously described problems of congenital malformations and neonatal adaptation syndrome seen in some pregnant women using SSRIs.2,3 Although it is important to acknowledge the limitations of case–control studies (including their inability to establish causation and possible confounding by unmeasured variables) and a possible recall bias, the relative risk increase (6-fold) seen here is dramatic. Nevertheless, the absolute risks of having a child with PPHN still remain low. Women taking SSRIs in the second half of their pregnancy will see their baseline risk of having a child with PPHN increase from 0.1% to 0.6%, an absolute increase of 0.5%. Although there is a 99.5% chance that such a woman's child would be unaffected, the number needed to harm is only 200. Women should be made aware of this potential adverse effect and the benefits and risks of treatment considered on a patient-by-patient basis. Infants born to women using the drugs should be monitored closely postpartum. It's not clear whether lower SSRI doses were protective. Alternate antidepressants had a similar but slightly lower risk of PPHN relative to controls (adjusted OR 3.2, 95% CI 1.3–7.4).


*    REFERENCES
Top
 REFERENCES
 

  1. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-87.[Abstract/Free Full Text]
  2. Williams M, Wooltorton E. Paroxetine (Paxil) and congenital malformations. CMAJ 2005;173:1320-1.[Free Full Text]
  3. Koren G, Matsui D, Einarson A, et al. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates? CMAJ 2005;172:1457-9.[Free Full Text]



This article has been cited by other articles:


Home page
 PediatricsHome page
E. Ferreira, A. M. Carceller, C. Agogue, B. Z. Martin, M. St-Andre, D. Francoeur, and A. Berard
Effects of Selective Serotonin Reuptake Inhibitors and Venlafaxine During Pregnancy in Term and Preterm Neonates
Pediatrics, January 1, 2007; 119(1): 52 - 59.
[Abstract] [Full Text] [PDF]

eLetters:

Read all eLetters

Confidence intervals of newborn pulmonary hypertension risk from SSRIs in utero
Pierre Biron
CMAJ, 14 Jun 2006 [Full text]
This Article
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
cmaj.060509v1
174/11/1555    most recent
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wooltorton, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wooltorton, E.
Related Collections
Right arrow Maternal-fetal medicine